Publication | Open Access

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Clinical Infectious DiseaseOpen-label RandomizedAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyAntiviral DrugHospitalized PatientsMedicineCovid-19